- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma (MM) Myelodysplastic syndromes (MDS) Mantle cell lymphoma (MCL)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 523KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 96KB)
Lenalidomide – November 2023
Lenalidomide: Capsule 20 mg; Lenalide®
Last updated
1 March 2024